NF-kB p65 anticorps

N° du produit ABIN105291

Détail du produit anti-NF-kB p65 anticorps

Antigène: NF-kB p65 (NFkBP65) (Nuclear Factor-kB p65 (NFkBP65))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp NF-kB p65 est non-conjugé

Application: Western Blotting (WB), ELISA, Immunofluorescence (IF), Gel Shift (GS)

Stérilité: Sterile filtered

Immunogène: This antibody was purified from whole rabbit serum prepared by repeated immunizations with the NFkB p65 peptide corresponding to the NLS of the human protein conjugated to KLH using maleimide. A residue of cysteine was added to the amino terminal end to facilitate coupling.

Isotype: IgG

Information d'application

Indications d'application: NFkB gel shift assays are assembled in 20µl reactions containing 0.28 pmoles NFkB oligo in 10mM Tris (pH 7.6), 50 mM NaCl, 0.5 mM EDTA, 1.0 mM DTT, 10% glycerol. Some procedures specify the addition of 0.05% NP-40. When using purified protein, 250-300 ng should be sufficient to produce a gel shifted complex, while 10µg HeLa nuclear extract is utilized. The gel shift reactions are then incubated at room temperature for 30 minutes. The complexes are resolved on Tris-Glycine acrylamide gels. Loading dye containing bromophenol blue and xylene cyanol should be added to the negative control reaction only, as these dyes can increase the dissociation of the NFkB complexes. When using HeLa nuclear extract as the source of binding proteins, two sequence-specific gel-shifted complexes are expected, consisting of p50/p50 homodimers and p50/p65 heterodimers. For cells expressing p52, p50, and p65, as many as four sequence-specific gel-shifted complexes could be observed (p52/p52, p50/p50, p52/p65, p50/p65), and if high levels of p65 are present, the p65/p65 homodimer may also be weakly detected. The following reagents have been observed to enhance NFkB binding in vitro: millimolar amounts of GTP and ATP, spermine, spermidine, barium or calcium ions, and µM amounts of Co+3(NH3)6.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1.0 mg/mL

Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2, 0.01% (w/v) Sodium Azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: -20 °C

Stockage commentaire: Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.

Références pour anticorps anti-NF-kB p65 (ABIN105291)

Yu, Chang, Liu, Li, Kevork, Al-Hezaimi, Graves, Park, Wang: "Wnt4 signaling prevents skeletal aging and inflammation by inhibiting nuclear factor-κB." dans: Nature medicine, Vol. 20, Issue 9, pp. 1009-17, (2014) (PubMed).

Graff, Ettayebi, Hardy: "Rotavirus NSP1 inhibits NFkappaB activation by inducing proteasome-dependent degradation of beta-TrCP: a novel mechanism of IFN antagonism." dans: PLoS pathogens, Vol. 5, Issue 1, pp. e1000280, (2009) (PubMed).

Lord, Savitsky, Sitcheran, Calame, Wright, Ting, Williams: "Blimp-1/PRDM1 mediates transcriptional suppression of the NLR gene NLRP12/Monarch-1." dans: Journal of immunology (Baltimore, Md. : 1950), Vol. 182, Issue 5, pp. 2948-58, (2009) (PubMed).

Liu, Ju, Willmarth, Casimiro, Ojeifo, Sakamaki, Katiyar, Jiao, Popov, Yu, Wu, Joyce, Wang, Pestell: "Nuclear factor-kappaB enhances ErbB2-induced mammary tumorigenesis and neoangiogenesis in vivo." dans: The American journal of pathology, Vol. 174, Issue 5, pp. 1910-20, (2009) (PubMed).

Sivaramakrishnan, Niranjali Devaraj: "Morin regulates the expression of NF-kappaB-p65, COX-2 and matrix metalloproteinases in diethylnitrosamine induced rat hepatocellular carcinoma." dans: Chemico-biological interactions, Vol. 180, Issue 3, pp. 353-9, (2009) (PubMed).

Liu, Li, Khoury, Colgan, Ibla: "Adenosine signaling mediates SUMO-1 modification of IkappaBalpha during hypoxia and reoxygenation." dans: The Journal of biological chemistry, Vol. 284, Issue 20, pp. 13686-95, (2009) (PubMed).

Kumar, Wu, Collier-Hyams, Kwon, Hanson, Neish: "The bacterial fermentation product butyrate influences epithelial signaling via reactive oxygen species-mediated changes in cullin-1 neddylation." dans: Journal of immunology (Baltimore, Md. : 1950), Vol. 182, Issue 1, pp. 538-46, (2008) (PubMed).

Abe, Hines, Zibari, Pavlick, Gray, Kitagawa, Grisham: "Mouse model of liver ischemia and reperfusion injury: method for studying reactive oxygen and nitrogen metabolites in vivo." dans: Free radical biology & medicine, Vol. 46, Issue 1, pp. 1-7, (2008) (PubMed).

Khoury, Ibla, Neish, Colgan: "Antiinflammatory adaptation to hypoxia through adenosine-mediated cullin-1 deneddylation." dans: The Journal of clinical investigation, Vol. 117, Issue 3, pp. 703-11, (2007) (PubMed).

Starkey, Haidacher, LeJeune, Zhang, Tieu, Choudhary, Brasier, Denner, Tilton: "Diabetes-induced activation of canonical and noncanonical nuclear factor-kappaB pathways in renal cortex." dans: Diabetes, Vol. 55, Issue 5, pp. 1252-9, (2006) (PubMed).

Détails sur NF-kB p65

Antigène: NF-kB p65 (NFkBP65) (Nuclear Factor-kB p65 (NFkBP65))

Autre désignation: NFkB p65 (NFkBP65 Produits)

Synonymes: anticorps C-Rel, anticorps NFKB3, anticorps p65, anticorps NFkB, anticorps c-rel, anticorps zgc:100833, anticorps Xrel2, anticorps Xrel3, anticorps rel, anticorps rel-A, anticorps rel2, anticorps rel3, anticorps v-rel, anticorps xrel, anticorps REL proto-oncogene, NF-kB subunit, anticorps RELA proto-oncogene, NF-kB subunit, anticorps v-rel reticuloendotheliosis viral oncogene homolog A (avian), anticorps v-rel avian reticuloendotheliosis viral oncogene homolog, anticorps v-rel avian reticuloendotheliosis viral oncogene homolog L homeolog, anticorps REL, anticorps RELA, anticorps Rela, anticorps Rel, anticorps rel, anticorps rel.L

Sujet: NFkB was originally identified as a factor that binds to the immunoglobulin kappa light chain enhancer in B cells.  It was subsequently found in non-B cells in an inactive cytoplasmic form consisting of NFkB bound to IkB. NFkB was originally identified as a heterodimeric DNA binding protein complex consisting of p65 (RelA) and p50 (NFKB1) subunits. Other identified subunits include p52 (NFKB2), c-Rel, and RelB. The p65, cRel, and RelB subunits are responsible for transactivation. The p50 and p52 subunits possess DNA binding activity but limited ability to transactivate. p52 has been reported to form transcriptionally active heterodimers with the NFkB subunit p65, similar to p50/p65 heterodimers. Low levels of p52 and p50 homodimers can also exist in cells. The heterodimers of p52/p65 and p50/p65 are regulated by physical inactivation in the cytoplasm by IkB-a. IkB-a binds to the p65 subunit, preventing nuclear localization and DNA binding.  IkB-a binding masks the NFkB nuclear localisation signal (NLS).   A broad range of external stimuli lead to activation of NFkB and set off signalling cascades that ultimately converge on the IkB kinase (IKK) complex. Activated IKK specifically and directly phosphorylates IkB-a and this phophorylation event targets IkB-a for degradation. As a consequence, NFkB NLS is uncovered and nuclear translocation occurs.
Synonyms: NFKB, nfkb, NF-kB, NF-kappaB, NFkappaB

ID gène: 5970, 223468676

UniProt: Q04206

Pathways: Signalisation NF-kappaB, Signalisation RTK, TCR Signaling, Signalisation TLR, Fc-epsilon Receptor Signaling Pathway, Neurotrophin Signaling Pathway, Activation of Innate immune Response, Cellular Response to Molecule of Bacterial Origin, Hepatitis C, Toll-Like Receptors Cascades, S100 Proteins